These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26580161)

  • 41. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A clinically validated diagnostic second-generation sequencing assay for detection of hereditary BRCA1 and BRCA2 mutations.
    Bosdet IE; Docking TR; Butterfield YS; Mungall AJ; Zeng T; Coope RJ; Yorida E; Chow K; Bala M; Young SS; Hirst M; Birol I; Moore RA; Jones SJ; Marra MA; Holt R; Karsan A
    J Mol Diagn; 2013 Nov; 15(6):796-809. PubMed ID: 24094589
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance.
    Manning AT; Wood C; Eaton A; Stempel M; Capko D; Pusic A; Morrow M; Sacchini V
    Br J Surg; 2015 Oct; 102(11):1354-9. PubMed ID: 26313374
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
    Dombernowsky SL; Weischer M; Freiberg JJ; Bojesen SE; Tybjaerg-Hansen A; Nordestgaard BG
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2339-42. PubMed ID: 19661094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
    King MC; Marks JH; Mandell JB;
    Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.
    De Leeneer K; Van Bockstal M; De Brouwer S; Swietek N; Schietecatte P; Sabbaghian N; Van den Ende J; Willocx S; Storm K; Blaumeiser B; Van Asperen CJ; Wijnen JT; Leunen K; Legius E; Michils G; Matthijs G; Blok MJ; Gomez-Garcia E; De Paepe A; Tischkowitz M; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 May; 133(1):393-8. PubMed ID: 22370629
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure?
    Bosch N; Junyent N; Gadea N; Brunet J; Ramon y Cajal T; Torres A; Graña B; Velasco A; Darder E; Mensa I; Balmaña J
    Breast; 2012 Dec; 21(6):755-60. PubMed ID: 22381151
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Management of hereditary ovarian cancer].
    Joó JG; Ládi S; Nagy BZ; Langmár Z
    Orv Hetil; 2011 Oct; 152(40):1596-608. PubMed ID: 21945869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer.
    Aloraifi F; Boland MR; Green AJ; Geraghty JG
    Surg Oncol; 2015 Jun; 24(2):100-9. PubMed ID: 25936246
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRCA1 and BRCA2: 1994 and beyond.
    Narod SA; Foulkes WD
    Nat Rev Cancer; 2004 Sep; 4(9):665-76. PubMed ID: 15343273
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic therapy options in BRCA mutation-associated breast cancer.
    Bayraktar S; Glück S
    Breast Cancer Res Treat; 2012 Sep; 135(2):355-66. PubMed ID: 22791366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
    Prucka SK; McIlvried DE; Korf BR
    Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
    Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
    J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes].
    Narod SA; Rodríguez AA
    Salud Publica Mex; 2011; 53(5):420-9. PubMed ID: 22218796
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
    Lancaster JM; Powell CB; Kauff ND; Cass I; Chen LM; Lu KH; Mutch DG; Berchuck A; Karlan BY; Herzog TJ;
    Gynecol Oncol; 2007 Nov; 107(2):159-62. PubMed ID: 17950381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.